HOME >> MEDICINE >> NEWS
Novel drugs help solve Gleevec resistance

SAN DIEGO - Two different novel targeted therapies can produce strong responses in patients who have become resistant to Gleevec(tm), the standard therapy for chronic myeloid leukemia (CML), researchers at The University of Texas M. D. Anderson Cancer Center are reporting.

Researchers say the benefits offered by these drugs, BMS-354825 and AMN107, appear to be promising for treatment of relapsed CML and offer an immediate effective option for the minority of patients who do not achieve an optimal response to Gleevec therapy.

M. D. Anderson Cancer Center, the only institution to have tested both of these novel compounds, undertook independent Phase I clinical trials of both agents. It conducted the study of BMS-354825 in conjunction with the University of California, Los Angeles, and the study of AMN107 with the University of Frankfurt, in Germany. The M. D. Anderson researchers will discuss their experiences using these agents in patients with leukemia at the American Society of Hematology (ASH) meeting.

BMS-354825 "shows remarkable activity"

In the study conducted at M. D. Anderson and at UCLA School of Medicine, the majority of patients with advanced, Gleevec-resistant CML have responded to the drug BMS-354825, says Moshe Talpaz, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson.

Of 11 patients with advanced "blast phase" CML, seven have had a hematologic response from the drug (defined as control of white blood cell counts). Of these, three patients experienced a complete hematologic response (disappearance of all findings consistent with advanced stage CML, and return of blood counts to normal), while two patients showed no evidence of leukemia. Two other patients had their CML downgraded to "chronic." Additionally, of the 11 patients, four have had a major "cytogenetic response" (defined as elimination of cells with the cancer-causing defect), and two had minor cytogenetic response
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-794-1584
University of Texas M. D. Anderson Cancer Center
5-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel antibiotic shows promise in shortening treatment duration of tuberculosis
3. Novel p53 gene-based therapy boosts immune system and reduces tumor size
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Smile Brands ... groups in the United States, today announced the grand opening of another affiliated ... , Patients will enjoy convenient hours, a comfortable office, and full-service care at ...
(Date:8/31/2020)... PASADENA, Calif. (PRWEB) , ... August 31, 2020 ... ... and leadership experience working, both directly with persons with autism and other developmental ... clinical expertise includes early intervention, parent education, adolescents with autism, school consultation, and ...
(Date:8/28/2020)... TUCSON, Ariz. (PRWEB) , ... August 28, 2020 ... ... helium-oxygen respiratory assist system designed to help treat patients with respiratory conditions, including ... a mixture of helium and oxygen, but it captures exhaled gas and scrubs ...
(Date:8/28/2020)... CHICAGO (PRWEB) , ... August 28, 2020 , ... ... its role in advising Adventist Health on its investment in Synchronous Health, a ... health company that combines the strength of human empathy with artificial intelligence (AI) ...
(Date:8/27/2020)... ... August 27, 2020 , ... Evolution Labs announced ... provide their students with Suite360:Mental Health and Prevention, a program developed to help ... Child Trafficking Prevention. , Florida schools and districts must provide their students with ...
Breaking Medicine News(10 mins):
(Date:8/28/2020)... ... 28, 2020 , ... Dr. Mark Surrey has been in practice for ... a clinical professor in the Department of OBGYN at UCLA’s David Geffen School of ... Coast Reproductive Society and is a Clinical Director of Fellowship Training for UCLA & ...
(Date:8/27/2020)... Texas (PRWEB) , ... August 27, 2020 , ... Austin ... Texas – is pleased to announce Dr. David Szalay, DDS, MD, has joined the ... treat patients in the new Pflugerville office, which is scheduled to open this fall. ...
(Date:8/27/2020)... ... , ... Trella Health, the leading source of provider referral ... marketing automation, and contact center solutions for senior living communities and post-acute care ... intelligence data and insights into Enquire’s CRM solution to serve as a powerful ...
Breaking Medicine Technology:
Cached News: